AbbVie (NYSE:ABBV) recently announced the availability of its drug SKYRIZI® in Canada for treating adults with ulcerative ...

AbbVie (NYSE:ABBV) is navigating significant shareholder activism as it urges opposition to two governance proposals ahead of ...

(RTTNews) - AbbVie Inc. (ABBV) Tuesday said that its Skyrizi approved for the treatment of adults with moderately to severely active ulcerative colitis is now available in Canada. Ulcerative ...

AbbVie’s former CEO Richard Gonzalez—who collected a $25.7 million payout for his final full year on the job in 2023—often ranked among the industry’s highest-paid CEOs during his tenure ...

We recently compiled a list of the 10 Stocks With At Least $10 Million In Insider Sales Recently. In this article, we are ...

AbbVie shares recently rebounded, supported by strong earnings, positive guidance, and a late 2024 dividend increase, indicating the potential for further gains. Despite a $3.5 billion impairment ...

AbbVie has signed a licensing deal with Danish-based Gubra to develop an obesity drug, marking the North Chicago company's first foray into the obesity market. Gubra will receive $350 million ...